The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...

Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...

Novo Nordisk A/S ... was the performance of the insulin division — long acting insulin revenues were up 28%, to $2.7bn, premix insulin up 13%, to $1.5bn, and fast-acting insulin up 16%, to ...

Novo Nordisk A/S NVO reported fourth-quarter ... which grew 31%. In Diabetes Care, fast-acting insulin Fiasp’s revenues were down 45%. NovoRapid revenues increased 62% and Human insulin ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth ... Instead, the beat came from insulin, thanks to favorable U.S. rebate adjustments, analysts said.

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying ... up at mealtimes with fast-acting insulins.